Trials / Completed
CompletedNCT00102973
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Phase III Randomized Study of TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Liposomal Doxorubicin (Doxil) as Second-Line Therapy in Platinum Refractory or Resistant Ovarian Cancer [ASSIST-3]
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 244 (actual)
- Sponsor
- Telik · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TLK286 in Combination with Carboplatin | Experimental Arm |
| DRUG | Doxorubicin HCl Liposome Injection | Active Comparator |
Timeline
- Start date
- 2004-12-01
- Primary completion
- 2008-07-01
- Completion
- 2008-07-01
- First posted
- 2005-02-07
- Last updated
- 2012-05-31
Locations
222 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00102973. Inclusion in this directory is not an endorsement.